Merus (NASDAQ:MRUS) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC lowered its position in shares of Merus (NASDAQ:MRUS) by 46.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,460 shares of the biotechnology company’s stock after selling 71,826 shares during the quarter. ADAR1 Capital Management LLC owned approximately 0.12% of Merus worth $3,425,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC lifted its holdings in Merus by 0.4% in the 4th quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company’s stock valued at $290,125,000 after purchasing an additional 25,595 shares in the last quarter. Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of Merus in the fourth quarter valued at about $3,524,000. Wells Fargo & Company MN lifted its stake in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after buying an additional 300 shares in the last quarter. Geode Capital Management LLC grew its stake in Merus by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company’s stock valued at $2,213,000 after acquiring an additional 540 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Merus by 9.1% in the 4th quarter. Alliancebernstein L.P. now owns 796,957 shares of the biotechnology company’s stock valued at $33,512,000 after acquiring an additional 66,326 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Stock Down 8.7 %

Shares of Merus stock opened at $38.11 on Monday. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -9.65 and a beta of 1.02. Merus has a 52-week low of $36.46 and a 52-week high of $61.61. The company’s 50-day simple moving average is $44.02 and its 200-day simple moving average is $45.72.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Equities research analysts anticipate that Merus will post -3.85 EPS for the current year.

Analyst Ratings Changes

MRUS has been the topic of a number of recent research reports. Guggenheim reissued a “buy” rating and set a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. Needham & Company LLC cut their target price on Merus from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. William Blair reissued an “outperform” rating on shares of Merus in a research note on Friday, February 28th. Bank of America lowered their target price on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Finally, Piper Sandler initiated coverage on Merus in a research report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Merus has an average rating of “Buy” and an average target price of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.